Novartis has named Bruno Strigini as president of Novartis Oncology, effective June 1, 2014. He joins Novartis from Merck & Co where he most recently served as president for Europe/Canada, a region comprising 37 countries with over 10,000 associates.

During his career, he has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included president of international operations, president of Japan and Asia-Pacific, and senior vice-president and head of global marketing and business development, as well as managing director positions in New Zealand, the UK, and Spain.

He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations as well as a member of the Académie Nationale de Pharmacie in France.

Source: Novartis